Stocks Health care VIR
NASDAQ · Health careVir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. brought in $303.2M of revenue over the twelve months to June 30, 2026, up 1,495.9% from a year earlier. It posted a net loss of $251.7M. In fiscal 2025 capital spending exceeded operating cash flow by $396.6M. At June 30, 2026 it held $278.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Vir Biotechnology, Inc. does
Vir Biotechnology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker VIR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $68.6M | -$438M | -$3.16 | -$396.6M |
| 2024 | $74.2M | -$522M | -$3.83 | -$453.7M |
| 2023 | $86.2M | -$615.1M | -$4.59 | -$800.4M |
| 2022 | $1.6B | $515.8M | $3.83 | $1.6B |
| 2021 | $1.1B | $528.6M | $3.96 | -$69.4M |
| 2020 | $76.4M | -$298.7M | -$2.51 | -$197.5M |
Latest SEC filings
What Vir Biotechnology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 24, 2026
- June 10, 2026
- May 28, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 6, 2026
- April 29, 2026Passive stake (5% or more) SCHEDULE 13G
Questions about VIR
What does Vir Biotechnology, Inc. do?
Vir Biotechnology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker VIR.
Is Vir Biotechnology, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $251.7M on revenue of $303.2M.
How much revenue does Vir Biotechnology, Inc. make?
Over the twelve months to June 30, 2026 Vir Biotechnology, Inc. reported revenue of $303.2M. That is 1,495.9% more than a year earlier.
When did Vir Biotechnology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from September 17, 2026.
Similar companies
Follow VIR
Get an email when Vir Biotechnology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow VIR: get an email when it filesWhere the numbers come from
Financial figures are the values Vir Biotechnology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.